1. Home
  2. SENEA vs ORIC Comparison

SENEA vs ORIC Comparison

Compare SENEA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seneca Foods Corp.

SENEA

Seneca Foods Corp.

HOLD

Current Price

$136.31

Market Cap

908.7M

ML Signal

HOLD

Logo Oric Pharmaceuticals Inc.

ORIC

Oric Pharmaceuticals Inc.

HOLD

Current Price

$8.37

Market Cap

837.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SENEA
ORIC
Founded
1949
2014
Country
United States
United States
Employees
6895
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
908.7M
837.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SENEA
ORIC
Price
$136.31
$8.37
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$19.73
AVG Volume (30 Days)
91.4K
1.2M
Earning Date
06-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.67
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.99
$4.65
52 Week High
$167.52
$14.93

Technical Indicators

Market Signals
Indicator
SENEA
ORIC
Relative Strength Index (RSI) 44.13 33.01
Support Level $112.17 $7.90
Resistance Level $148.36 $13.89
Average True Range (ATR) 5.57 0.50
MACD -0.00 -0.10
Stochastic Oscillator 24.71 4.02

Price Performance

Historical Comparison
SENEA
ORIC

About SENEA Seneca Foods Corp.

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Share on Social Networks: